FR2552326B1 - Composition d'extrait soluble de pyridine et d'endotoxine detoxifiee raffinee et son utilisation - Google Patents

Composition d'extrait soluble de pyridine et d'endotoxine detoxifiee raffinee et son utilisation

Info

Publication number
FR2552326B1
FR2552326B1 FR8414533A FR8414533A FR2552326B1 FR 2552326 B1 FR2552326 B1 FR 2552326B1 FR 8414533 A FR8414533 A FR 8414533A FR 8414533 A FR8414533 A FR 8414533A FR 2552326 B1 FR2552326 B1 FR 2552326B1
Authority
FR
France
Prior art keywords
composition
pyridine
soluble extract
detoxified endotoxin
refined detoxified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8414533A
Other languages
English (en)
French (fr)
Other versions
FR2552326A1 (fr
Inventor
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2552326A1 publication Critical patent/FR2552326A1/fr
Application granted granted Critical
Publication of FR2552326B1 publication Critical patent/FR2552326B1/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
FR8414533A 1983-09-23 1984-09-21 Composition d'extrait soluble de pyridine et d'endotoxine detoxifiee raffinee et son utilisation Expired FR2552326B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (2)

Publication Number Publication Date
FR2552326A1 FR2552326A1 (fr) 1985-03-29
FR2552326B1 true FR2552326B1 (fr) 1988-05-13

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8414533A Expired FR2552326B1 (fr) 1983-09-23 1984-09-21 Composition d'extrait soluble de pyridine et d'endotoxine detoxifiee raffinee et son utilisation

Country Status (23)

Country Link
US (1) US4663306A (enExample)
JP (1) JPS60120817A (enExample)
KR (1) KR870000843B1 (enExample)
AT (1) AT385659B (enExample)
AU (1) AU566234B2 (enExample)
BE (1) BE900650A (enExample)
CA (1) CA1244765A (enExample)
CH (1) CH664897A5 (enExample)
DE (1) DE3434766C2 (enExample)
DK (1) DK446684A (enExample)
ES (1) ES8608872A1 (enExample)
FI (1) FI843716L (enExample)
FR (1) FR2552326B1 (enExample)
GB (1) GB2149301B (enExample)
HU (1) HU192585B (enExample)
IL (1) IL73034A (enExample)
IN (1) IN157240B (enExample)
IT (1) IT1179444B (enExample)
NL (1) NL8402902A (enExample)
NO (1) NO843776L (enExample)
NZ (1) NZ209635A (enExample)
SE (1) SE8404707L (enExample)
ZA (1) ZA847405B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596990A1 (fr) * 1986-04-15 1987-10-16 Ribi Immunochem Research Inc Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
ATE210989T1 (de) * 1993-08-27 2002-01-15 Vetrepharm Inc Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
BE1007823A3 (fr) * 1993-12-10 1995-10-31 Anda Biolog Sa Utilisation d'une composition comprenant au moins un antigene et/ou un ou plusieurs fragments de cet antigene pour l'obtention d'un medicament destine au traitement et/ou a la prevention du cancer.
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (de) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Verwendung einer Lösung zur Desaktivierung von Endotoxinen
JP4335435B2 (ja) 1997-08-05 2009-09-30 バイオニケ ライフ サイエンシーズ インコーポレイテッド 細胞増殖および細胞死を調節する組成物および方法
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
US7534443B1 (en) 1998-07-16 2009-05-19 Ichiro Azuma Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
PT1238070E (pt) * 1999-12-13 2007-11-06 Bioniche Life Sciences Inc Oligonucleótidos sintéticos úteis sob o ponto de vista terapêutico
EP1250152B1 (en) * 1999-12-28 2013-05-15 Bioniche Urology IP Inc. Synergistic composition containing hyaluronic acid in the treatment of cancer
LU90996B1 (en) * 2000-07-11 2003-01-08 Bayer Ag Use of the strains of the parapox ovis virus against fibrosis
CA2478106A1 (en) * 2002-03-05 2003-09-12 Cell-Medicine, Inc. Solidified tissue immunoadjuvant
EP1547607A4 (en) * 2002-08-02 2008-11-26 Dainippon Sumitomo Pharma Co PREPARATION OF A COMPONENT OF BACTERIA CELL WALL SKELETON
FR2848223B1 (fr) * 2002-12-09 2005-02-25 Centre Nat Rech Scient Nouveau procede d'isolement des endotoxines.
US20060127518A1 (en) * 2003-09-05 2006-06-15 Shenyang Sunbellcom Bio-Pharmaceutical Co. Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
CN118979001A (zh) 2014-06-17 2024-11-19 皇冠实验室有限公司 经遗传修饰的细菌和用于细菌的遗传修饰的方法
WO2017147507A1 (en) 2016-02-24 2017-08-31 Xycrobe Therapeutics, Inc. Skin probiotic formulation
WO2019036663A1 (en) * 2017-08-17 2019-02-21 University Of Delaware FURANE COMPOSITIONS AND METHODS OF MAKING THE SAME
BR112022026237A2 (pt) 2020-06-23 2023-01-17 Crown Laboratories Inc Formulações probióticas para a pele

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (enExample) * 1972-06-20 1973-12-27
FR2269962B1 (enExample) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (ja) * 1979-08-30 1983-01-08 株式会社 目黒研究所 糖蛋白ｗｅｎａｃ及びその製造法
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2596990A1 (fr) * 1986-04-15 1987-10-16 Ribi Immunochem Research Inc Adjuvant immunologique a base d'emulsion de lipide et d'un adjuvant bacterien
FR2598622A1 (fr) * 1986-04-15 1987-11-20 Ribi Immunochem Research Inc Adjuvants immunologiques pour vaccins polysaccharidiques

Also Published As

Publication number Publication date
DE3434766C2 (de) 1987-05-14
DK446684D0 (da) 1984-09-19
CA1244765A (en) 1988-11-15
JPS60120817A (ja) 1985-06-28
IN157240B (enExample) 1986-02-15
NL8402902A (nl) 1985-04-16
FI843716A0 (fi) 1984-09-21
HUT35521A (en) 1985-07-29
FR2552326A1 (fr) 1985-03-29
AU3340084A (en) 1985-03-28
IT8448894A0 (it) 1984-09-24
NZ209635A (en) 1989-01-27
AU566234B2 (en) 1987-10-15
US4663306A (en) 1987-05-05
ES8608872A1 (es) 1986-07-16
KR870000843B1 (ko) 1987-04-25
NO843776L (no) 1985-03-25
IT1179444B (it) 1987-09-16
DE3434766A1 (de) 1986-04-30
GB2149301B (en) 1988-06-22
KR850002404A (ko) 1985-05-13
BE900650A (fr) 1985-03-21
DK446684A (da) 1985-03-24
AT385659B (de) 1988-05-10
ATA302384A (de) 1987-10-15
FI843716A7 (fi) 1985-03-24
JPS6254775B2 (enExample) 1987-11-17
IL73034A (en) 1988-11-15
ZA847405B (en) 1985-05-29
FI843716L (fi) 1985-03-24
SE8404707D0 (sv) 1984-09-20
HU192585B (en) 1987-06-29
GB2149301A (en) 1985-06-12
ES536167A0 (es) 1986-07-16
GB8423993D0 (en) 1984-10-31
CH664897A5 (de) 1988-04-15
SE8404707L (sv) 1985-03-24

Similar Documents

Publication Publication Date Title
GB2149301B (en) Pyridine-soluble extract - refined detoxified endotoxin composition and use
IT1127253B (it) Proteine purificate e procedimento per la loro preparazione
FR2509175B1 (fr) Preparation therapeutique ayant d'excellentes proprietes d'absorption
BE880905A (fr) Compositions influencant le systeme nerveux central et leur methode d'utilisation
FR2527443B1 (fr) Composition contenant de l'endotoxine raffinee et medicament la contenant
IT1114488B (it) Perfezionamento nelle protesi di articolazioni
EP0283505A4 (en) Vaccine and method of preparation.
IT1124875B (it) Mezzi per l'attivazione e la disattivazione di innesti
BE885278A (fr) Installation d'extraction et de havage
JPS57169482A (en) Imidazopyrimidine derivative and application to medicine
FR2499410B1 (fr) Vaccin contre l'avortement enzootique chez les brebis et son procede de preparation
FR2550945B1 (fr) Compositions d'endotoxines purifiees et leur application pharmacologique
BE866355A (fr) Nouvelle proteine et son procede d'isolement
DE3750642D1 (de) Verfahren und Zusammensetzungen betreffend regressions-assoziierte Antigene.
FI834215A7 (fi) Sydänlääkkeenä käyttökelpoisia 2(1H)- pyridinoneja sekä niiden valmistus.
MA19965A1 (fr) 3',5'-diarabinosides, leur preparation et leur application en therapeutique
PT69486A (fr) Procede de preparation d'esters benzylideniques et leur application en therapeutique
BE880885A (fr) Composition therapeutique antithrombotique
BE894537A (fr) Derives d'esters de di-et polysulfosuccinates, leur preparation et leur utilisation
ES265781Y (es) "dispositivo para composicion de muebles y estanterias".
JPS53103892A (en) Recoverable fish shelters made of used tired and having captureness also
IT8619144V0 (it) Sistema di fissaggio dei petali per la composizione di un fiore artificiale da applicare alle calzature o all'abbigliamento in genere
ES523253A0 (es) "metodo de preparar antigenos glicorrelacionados".
BE873280A (fr) 2-beta-(p-chlorophenoxy)isobutyrate) de 2,6-pyridinedimethanol, applications therapeutiques et procede de preparation
BE882123A (fr) Derives d'amino-thiazolines et leur application en therapeutique

Legal Events

Date Code Title Description
ST Notification of lapse